Russell Investments Group Ltd. boosted its position in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 19.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 212,572 shares of the biotechnology company’s stock after purchasing an additional 34,405 shares during the period. Russell Investments Group Ltd.’s holdings in Corcept Therapeutics were worth $24,495,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Corcept Therapeutics in the 2nd quarter valued at about $27,000. Provenance Wealth Advisors LLC bought a new position in shares of Corcept Therapeutics during the 3rd quarter worth approximately $38,000. Fulcrum Asset Management LLP lifted its position in shares of Corcept Therapeutics by 520.7% during the 3rd quarter. Fulcrum Asset Management LLP now owns 571 shares of the biotechnology company’s stock worth $66,000 after buying an additional 479 shares in the last quarter. Root Financial Partners LLC purchased a new position in shares of Corcept Therapeutics in the 3rd quarter worth approximately $85,000. Finally, State of Wyoming boosted its stake in shares of Corcept Therapeutics by 29.5% in the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock worth $33,000 after buying an additional 186 shares during the last quarter. 93.61% of the stock is owned by institutional investors.
Corcept Therapeutics Stock Performance
CORT opened at $70.07 on Wednesday. The firm has a market cap of $7.67 billion, a P/E ratio of 54.50 and a beta of 0.54. The firm has a 50-day moving average of $101.97 and a 200 day moving average of $76.68. Corcept Therapeutics Incorporated has a fifty-two week low of $28.66 and a fifty-two week high of $126.38.
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The biotechnology company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.17. The business had revenue of $340.47 million during the quarter, compared to the consensus estimate of $339.12 million. Corcept Therapeutics had a net margin of 16.53% and a return on equity of 22.56%. The firm’s quarterly revenue was up 64.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.16 earnings per share. Equities research analysts predict that Corcept Therapeutics Incorporated will post 1.97 earnings per share for the current fiscal year.
Insider Activity
In related news, Director Kimberly Park sold 26,685 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $122.55, for a total value of $3,270,246.75. Following the sale, the director owned 30,000 shares of the company’s stock, valued at approximately $3,676,500. The trade was a 47.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Roberto Vieira sold 58,333 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $110.76, for a total transaction of $6,460,963.08. Following the completion of the sale, the insider directly owned 4,242 shares in the company, valued at $469,843.92. This trade represents a 93.22% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 259,435 shares of company stock worth $28,492,179. 20.70% of the stock is owned by insiders.
Analyst Ratings Changes
Several equities analysts have recently issued reports on CORT shares. Wall Street Zen raised Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 1st. Zacks Research downgraded Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 27th. Wolfe Research lowered Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price target on the stock. in a report on Monday, July 27th. Weiss Ratings raised Corcept Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, November 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $165.00 price objective on shares of Corcept Therapeutics in a research report on Friday, September 18th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $139.50.
Check Out Our Latest Stock Report on Corcept Therapeutics
Corcept Therapeutics Company Profile
Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body’s response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.
Further Reading
- Five stocks we like better than Corcept Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report).
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
